NextGen 2024: Weaning meds when disease is controlled Session Part 2
AI Summary
Key Insights
- The document discusses the weaning therapy in Systemic Juvenile Idiopathic Arthritis (SJIA).
- Patient cases and patterns of SJIA are presented, including recurrent, persistent, and continuous therapy needs.
- The information highlights the importance of following clinical clues, lab results, and genetic/biologic factors in understanding and managing SJIA.
- Gaps in the current approach are identified such as improving genetic test interpretation, understanding epigenetics, and addressing drug efficacy issues.
- Multidisciplinary care, rapid disease control, and shared decision-making are essential aspects of SJIA management.
#Stillsdisease#Sjiafoundation#Sjia#Curesjia







